AbCellera Biologics Receives Health Canada Approval for Trial

AbCellera Biologics ( (ABCL) ) has issued an update.

On May 14, 2025, AbCellera Biologics announced it received a No Objection Letter from Health Canada for its Clinical Trial Application for ABCL635, a novel antibody antagonist targeting the neurokinin 3 receptor for treating vasomotor symptoms associated with menopause. The Phase 1 clinical trial, expected to start in Q3 2025, will assess the safety and pharmacokinetics of ABCL635, marking a significant step in AbCellera’s efforts to offer a non-hormonal treatment for menopause-related hot flashes, potentially impacting the well-being of millions of women.

The most recent analyst rating on (ABCL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.

Spark’s Take on ABCL Stock

According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.

AbCellera Biologics faces significant financial and technical challenges, with declining revenues and weak technical indicators. Strategic advancements in drug development and a strong liquidity position offer some potential, but current valuation metrics are concerning. The recent patent appeal win provides a positive note, but substantial improvements are needed for a better outlook.

To see Spark’s full report on ABCL stock, click here.

More about AbCellera Biologics

AbCellera Biologics Inc. is a company that discovers and develops antibody medicines for various therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. The company integrates technology, data science, and interdisciplinary teams to tackle complex antibody discovery challenges and focuses on advancing both internal and collaborative drug development programs.

Average Trading Volume: 4,492,330

Technical Sentiment Signal: Sell

Current Market Cap: $614.9M

See more insights into ABCL stock on TipRanks’ Stock Analysis page.